8-K 1 pal84590.txt FORM 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 - - - - - - - - - - - FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 September 19, 2002 Date of Report (Date of Earliest Event Reported) GENELABS TECHNOLOGIES, INC. (Exact Name of Registrant as Specified in its Charter) 0-19222 94-3010150 (Commission File Number) (IRS Employer Identification No.) 505 Penobscot Drive Redwood City, California 94063 (Address of Principal Executive Offices) (Zip Code) (650) 369-9500 (Registrant's Telephone Number, including Area Code) Item 5. Other Events On September 19, 2002, Genelabs Technologies, Inc. ("Genelabs") issued a press release announcing it has signed an agreement with Patheon Inc. for the commercial supply of Prestara(TM), Genelabs' drug candidate for systemic lupus erythematosus. Item 7. Exhibits EXHIBIT NO. DESCRIPTION 99.1 Press Release dated September 19, 2002. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunder duly authorized. Dated: September 19, 2002 GENELABS TECHNOLOGIES, INC. By: /s/ Heather Criss Keller -------------------------- Name: Heather Criss Keller Title: Vice President, General Counsel EXHIBIT INDEX EXHIBIT NO. DESCRIPTION 99.1 Press Release dated September 19, 2002.